Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 14/20 | 0.50 |
| ▸ | CRBN | Q96SW2 | 14/20 | 0.50 |
| ▸ | TNF | P01375 | 1/20 | 0.39 |
| ▸ | IL1B | P01584 | 1/20 | 0.39 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.39 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.39 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.39 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4940401 | 0.91 | DDB1 (0.49) | DDB1CRBNTNFIL1BTBXA2R | |
| SCHEMBL4929988 | 0.90 | DDB1 (0.49) | DDB1CRBNTNFIL1BTBXA2R | |
| SCHEMBL4935531 | 0.89 | CRBN (0.44) | DDB1CRBNTNFIL1BTBXA2R | |
| SCHEMBL4929873 | 0.89 | MAP1LC3B (0.43) | DDB1CRBNIKZF3MAP1LC3BALDH1A1 | |
| SCHEMBL19889425 | 0.86 | DDB1 (0.53) | DDB1CRBNTNFIL1BTBXA2R | |
| SCHEMBL18923342 | 0.85 | DDB1 (0.48) | DDB1CRBNTNFIL1BTBXA2R | |
| SCHEMBL19889409 | 0.84 | DDB1 (0.43) | DDB1CRBNTNFIL1BTBXA2R | |
| SCHEMBL18923355 | 0.83 | DDB1 (0.43) | DDB1CRBNTNFIL1BTBXA2R | |
| SCHEMBL4931953 | 0.82 | DDB1 (0.47) | DDB1CRBNTNFIL1BTBXA2R | |
| SCHEMBL19889406 | 0.82 | DDB1 (0.42) | DDB1CRBNTNFIL1BTBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10406147-B2 | Piperidine-2, 6-dione derivatives and their use as tumor necrosis factor inhibitors | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2019-09-10 | — | — | US | disclosed |
| US-10166222-B2 | Piperidine-2, 6-dione derivatives and their use as tumor necrosis factor inhibitors | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2019-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10406147-B2 | Piperidine-2, 6-dione derivatives and their use as tumor necrosis factor inhibitors | TNF, TNFRSF1A, TNFRSF9 | DDB1 2336/4885CRBN 896/4885TNF 1/4885 |
| US-10166222-B2 | Piperidine-2, 6-dione derivatives and their use as tumor necrosis factor inhibitors | TNFRSF1A, TNFRSF9, NGFR | DDB1 2770/4885CRBN 1007/4885TNF 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.